- Home
- VIVS vs GLMD Comparison
VIVS vs GLMD Comparison
Compare VIVS & GLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIVS
- GLMD
- Stock Information
- Founded
- VIVS 2007
- GLMD 2000
- Country
- VIVS United States
- GLMD Israel
- Employees
- VIVS N/A
- GLMD N/A
- Industry
- VIVS Biotechnology: Biological Products (No Diagnostic Substances)
- GLMD Biotechnology: Pharmaceutical Preparations
- Sector
- VIVS Health Care
- GLMD Health Care
- Exchange
- VIVS Nasdaq
- GLMD Nasdaq
- Market Cap
- VIVS 3.6M
- GLMD 3.0M
- IPO Year
- VIVS N/A
- GLMD 2014
- Fundamental
- Price
- VIVS $1.80
- GLMD $1.43
- Analyst Decision
- VIVS
- GLMD Hold
- Analyst Count
- VIVS 0
- GLMD 1
- Target Price
- VIVS N/A
- GLMD N/A
- AVG Volume (30 Days)
- VIVS 137.3K
- GLMD 1.7M
- Earning Date
- VIVS 06-06-2025
- GLMD 05-22-2025
- Dividend Yield
- VIVS N/A
- GLMD N/A
- EPS Growth
- VIVS N/A
- GLMD N/A
- EPS
- VIVS N/A
- GLMD N/A
- Revenue
- VIVS $122,000.00
- GLMD N/A
- Revenue This Year
- VIVS $59.08
- GLMD N/A
- Revenue Next Year
- VIVS $18.24
- GLMD N/A
- P/E Ratio
- VIVS N/A
- GLMD N/A
- Revenue Growth
- VIVS N/A
- GLMD N/A
- 52 Week Low
- VIVS $1.56
- GLMD $1.15
- 52 Week High
- VIVS $21.96
- GLMD $23.80
- Technical
- Relative Strength Index (RSI)
- VIVS N/A
- GLMD 51.98
- Support Level
- VIVS N/A
- GLMD $1.36
- Resistance Level
- VIVS N/A
- GLMD $1.53
- Average True Range (ATR)
- VIVS 0.00
- GLMD 0.09
- MACD
- VIVS 0.00
- GLMD 0.03
- Stochastic Oscillator
- VIVS 0.00
- GLMD 72.78
About VIVS VivoSim Labs Inc. Common Stock
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases.
About GLMD Galmed Pharmaceuticals Ltd.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.